{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/6adf577efeb8d1e39cf8e58e?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1793021797021-b276d73d-89fc-475e-99be-5ca060df4c79.jpeg?height=200","description":"<p>This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk. </p><p><br></p><p>In this panel: </p><p>- Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill </p><p>- How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk </p><p>- How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two </p><p>- Fixed platforms with flexible indications, and when one facility can serve many </p><p>- The latest build, buy or partner calls each CEO has made </p><p>- Data or instinct: how they decide where to invest next </p><p>- The one thing each of them would remove from pharma manufacturing</p><p><br></p><p>Be sure to watch to the end for the quickfire round. </p><p><br></p><p>Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&amp;utm_medium=referral&amp;utm_campaign=hln27cpw-cl-arto </p><p><br></p><p>🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026. </p><p><br></p><p>Follow ARTO </p><p>LinkedIn: https://www.linkedin.com/company/artotalent </p><p>Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng </p><p>Instagram: https://www.instagram.com/arto.talent </p><p>TikTok: https://www.tiktok.com/@artotalent </p><p>Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 </p><p>Website: https://arto-talent.com/ </p><p>YouTube: https://www.youtube.com/@artotalent </p><p>Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4 </p><p><br></p><p>The panel :</p><p>Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/ </p><p>Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/ </p><p>Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/ </p><p>Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/ </p><p><br></p><p>Timestamps:</p><p>0:00 Intro </p><p>0:15 Welcome to the CEO’s Weekly Challenge </p><p>0:50 How do you weigh capacity risk against indication risk? </p><p>6:50 ten23 health: the science, not the disease </p><p>9:06 Do biosimilars take indication risk out? </p><p>10:56 Curapath’s ALS customer: from 16 conjugates to four </p><p>12:28 Fixed platform, flexible indications </p><p>15:31 Fast, flexible capacity: real or a marketing ploy? </p><p>23:29 Biosimilars: flexibility or analytical rigour? </p><p>26:03 Can one facility serve many indications and be best in class? </p><p>28:29 The latest build, buy or partner call </p><p>33:35 Data or instinct? </p><p>40:34 Quickfire: one thing to remove from pharma manufacturing </p><p><br></p><p>#MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery</p>","author_name":"ARTO Talent"}